Boulder-based life sciences company expands to larger space with new hub
(Louisville, CO) – October 5, 2022 – Koelbel and Company, a family-owned, Colorado-based real estate company with a 70-year history, announced today that Biodesix, Inc., a leading data-driven diagnostic testing solutions company dedicated to improving medical care for patients with lung disease, will be the sole tenant of a former Kohl’s building in Louisville located at 919 West Dillion. The growing life sciences company will be leasing the 80,000 square foot building on 13 acres in the heart of the Centennial Valley in Boulder County – one of the hubs for life sciences in the country.
“Koelbel and Company is at the forefront of identifying innovative real estate trends and meeting the ever-changing demands of the market and we recognize that Boulder County is attracting the top life sciences talent and companies across the country,” said Buz Koelbel, President of Koelbel and Company. “We are excited to partner with Biodesix, a local company looking to expand in this top market on this innovative project.”
An extensive renovation of the former Kohl’s building will take place in conjunction with the tenant improvements including updates to exterior façade, addition of windows, and an outdoor break area for use by the Biodesix team and a state-of-the-art diagnostic testing laboratory to perform tests to help improve care for patients with lung nodules and lung cancer.
“As a patient-centric, mission-driven diagnostic company, community is core to the Biodesix team and culture” says Scott Hutton, Chief Executive Officer of Biodesix. “Continued growth and success in transforming the cancer standard of care, while improving cancer treatment outcomes with personalized diagnostics, created an opportunity for the Biodesix team to expand out of our current location in Boulder. We are excited to work with Koelbel to redevelop and revitalize this location in Louisville, as many of our Biodesix team members are already neighbors and active members of the community. Our team was directly impacted by the Marshall Fire, and Biodesix was proud to be part of the disaster recovery efforts. We are excited to call Louisville our new home and look forward to being an active member of the community, positively contributing to the rebuild and future growth in Louisville and the surrounding community.”
Koelbel will utilize its 70 years of expertise to make strategic improvements to the building over the next year with enhancements to the interior and exterior, break room, common areas and outdoor spaces. DLR Architects have been retained to execute a new state of the art laboratory concept in the space. Erik Abrahamson, from CBRE represented Koelbel and Company, and Steve Billingmeier with Cushman and Wakefield represented Biodesix.
“Biodesix is a wonderful addition to Louisville’s vibrant and diverse business environment,” said Mayor of Louisville, Ashley Stolzmann. “This innovative company is pioneering critical advancements in the diagnostics testing space, and we are proud and excited to welcome them to our community.”
More information is available at https://www.koelbelco.com.
About Koelbel and Company
Founded as a residential brokerage company in 1952 and now a full-service real estate company with developed properties spanning from Vail and Winter Park to Louisville and Denver, Koelbel and Company has helped change the face of the Centennial State. Now in its third generation, the family owned Koelbel and Company continues to place its indelible mark on the Colorado landscape and beyond with innovative residential and commercial developments that blend ageless values with pacesetting design. For more information visit www.koelbelco.com.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.
###
Media Contact: Courtney Lis
courtney@vocapr.com
970.581.6231
Back To Press Room
